Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

HIV vaccine development--improving on natural immunity.

Johnston MI, Fauci AS.

N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. No abstract available.

2.

AIDS/HIV. A boost for HIV vaccine design.

Burton DR, Weiss RA.

Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693. No abstract available.

PMID:
20705840
3.

Infectious disease. An enterprising time for HIV vaccine research.

Cohen J.

Science. 2012 Sep 21;337(6101):1446. No abstract available. Erratum in: Science. 2012 Nov 9;338(6108):742.

PMID:
22997300
4.

Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.

Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF.

AIDS. 2011 Jun 19;25(10):1249-64. doi: 10.1097/QAD.0b013e328347f9fa.

PMID:
21516028
5.

Vaccines and immunology. Recent advances in HIV/AIDS vaccine development.

Landay A, Heeney JL.

AIDS. 2001;15 Suppl 5:S101-3. Review. No abstract available.

PMID:
11816157
6.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
7.

Challenges for structure-based HIV vaccine design.

Schief WR, Ban YE, Stamatatos L.

Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Review.

PMID:
20048708
8.

HIV Vaccines: One Step Closer.

Low MS, Tarlinton D.

Trends Mol Med. 2017 Jan;23(1):1-3. doi: 10.1016/j.molmed.2016.10.006. Epub 2016 Nov 23.

PMID:
27889424
9.

Tiny steps towards an HIV vaccine.

Willyard C.

Nature. 2010 Jul 15;466(7304):S8. doi: 10.1038/nature09238. No abstract available.

PMID:
20631706
10.
11.

Current world literature.

[No authors listed]

Curr Opin HIV AIDS. 2009 Sep;4(5):453-7. doi: 10.1097/COH.0b013e3283306278. No abstract available.

PMID:
20046137
12.

Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines.

Albert J, Chiodi F, Fenyö EM.

J Intern Med. 2007 Jul;262(1):2-4. Review. No abstract available.

13.

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

Korber B, Gnanakaran S.

Curr Opin HIV AIDS. 2009 Sep;4(5):408-17. doi: 10.1097/COH.0b013e32832f129e. Review.

PMID:
20048705
14.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

15.

In vivo protection by broadly neutralizing HIV antibodies.

van Gils MJ, Sanders RW.

Trends Microbiol. 2014 Oct;22(10):550-1. doi: 10.1016/j.tim.2014.08.006. Epub 2014 Aug 26.

PMID:
25169020
16.

The RV144 Thai HIV vaccine trial.

Plotkin SA.

Hum Vaccin. 2010 Feb;6(2):159. Epub 2010 Feb 18. No abstract available.

PMID:
20431337
17.

Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword.

Füst G.

Vaccine. 2008 Jun 6;26(24):2949-50. doi: 10.1016/j.vaccine.2008.02.003. Epub 2008 Feb 13. No abstract available.

PMID:
18321613
18.
19.

AIDS research. Novel antibody response may explain HIV vaccine success.

Cohen J.

Science. 2011 Sep 16;333(6049):1560. doi: 10.1126/science.333.6049.1560. No abstract available.

PMID:
21921167
20.

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

Montefiori DC, Mascola JR.

Curr Opin HIV AIDS. 2009 Sep;4(5):347-51. doi: 10.1097/COH.0b013e32832f4a4d. Review.

Supplemental Content

Support Center